English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
 
 
DownloadE-Mail
  Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma

Bendtsen, M. A. F., Grimm, D., Bauer, J., Wehland, M., Wise, P., Magnusson, N. E., et al. (2017). Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma. International Journal of Molecular Sciences, 18(8): 1736. doi:10.3390/ijms18081736.

Item is

Files

show Files
hide Files
:
ijms-18-01736.pdf (Publisher version), 568KB
Name:
ijms-18-01736.pdf
Description:
-
OA-Status:
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
License:
-

Locators

show

Creators

show
hide
 Creators:
Bendtsen, Mathias Alro Fichtner1, Author
Grimm, Daniela1, Author
Bauer, Johann2, Author           
Wehland, Markus1, Author
Wise, Petra1, Author
Magnusson, Nils E.1, Author
Infanger, Manfred1, Author
Krueger, Marcus1, Author
Affiliations:
1external, ou_persistent22              
2Scientific Service Groups, Max Planck Institute of Biochemistry, Max Planck Society, ou_1565170              

Content

show
hide
Free keywords: ANTI-ANGIOGENIC THERAPY; TARGETED THERAPY; OPEN-LABEL; SUNITINIB; CANCER; COMBINATION; TRIAL; INHIBITION; MANAGEMENT; BIOMARKERBiochemistry & Molecular Biology; Chemistry; metastatic renal cell carcinoma; lenvatinib; everolimus; hypertension; multikinase inhibitors; mTOR inhibitor; vascular endothelial growth factor;
 Abstract: Multikinase inhibitors (MKI) and mammalian target of rapamycin (mTOR) inhibitors prolong progression-free (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC) by reducing angiogenesis and tumor growth. In this regard, the MKI lenvatinib and the mTOR inhibitor everolimus proved effective when applied alone, but more effective when they were administered combined. Recently, both drugs were included in clinical trials, resulting in international clinical guidelines for the treatment of mRCC. In May 2016, lenvatinib was approved by the American Food and Drug Administration (FDA) for the use in combination with everolimus, as treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. A major problem of treating mRCC with lenvatinib and everolimus is the serious adverse event (AE) of arterial hypertension. During the treatment with everolimus and lenvatinib combined, 42% of the patients developed hypertension, while 10% of the patients treated with everolimus alone and 48% of the of the lenvatinib only treated patients developed hypertension. Lenvatinib carries warnings and precautions for hypertension, cardiac failure, and other adverse events. Therefore, careful monitoring of the patients is necessary.

Details

show
hide
Language(s): eng - English
 Dates: 2017
 Publication Status: Published online
 Pages: 12
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: ISI: 000408897400137
DOI: 10.3390/ijms18081736
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: International Journal of Molecular Sciences
  Abbreviation : Int. J. Mol. Sci.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Basel, Switzerland : MDPI AG
Pages: - Volume / Issue: 18 (8) Sequence Number: 1736 Start / End Page: - Identifier: ISSN: 1422-0067
CoNE: https://pure.mpg.de/cone/journals/resource/1422-0067